Intercept sues Apotex over Ocaliva generic

Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva (obeticholic acid).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Takeda, Bayer settle $173m Adynovate suit

20 May 2021 Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.

Americas

Orexo sues Sun Pharma over opioid dependence generic

16 September 2020 Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.

Big Pharma

Bayer, Apotex settle suit over cancer drug patent

13 August 2020 Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Intercept sues Apotex over Ocaliva generic

More on this story

Editor's picks

Editor's picks

More features